Stereotactic evacuation of hypertensive cerebellar hemorrhage using plasminogen activator.
Treatment for hypertensive cerebellar hemorrhage still remains controversial as to whether direct surgical procedure is indicated or not. This is so even after the introduction of CT scan which easily demonstrates the location and size of the hematoma and the presence of hydrocephalus. In this paper, we present our experience of 20 patients with cerebellar hemorrhage treated by stereotactic evacuation using Komai's CT-stereotactic apparatus. All the patients had vertigo, cerebellar symptoms, dysfunction of brain stem or consciousness disturbance. The hematomas on CT scan were more than 28 mm in diameter. Acute obstructive hydrocephalus occurred in 90% of the patients with hematoma 40 mm or larger in size. The patients with consciousness disturbance were immediately operated on after the attack, and a drainage tube was placed in the hematoma cavity to drain cerebrospinal fluid and liquefied hematoma for one to eight days. On the other hand, when patients with hematoma around 30 mm in diameter complained vertigo for about two weeks, they also were operated on stereotactically. After the operation, their symptoms improved rapidly. The stereotactic operation could aspirate about 85% of the estimated hematoma volume and improved the hydrocephalus, except in one case in which the patient rapidly deteriorated to coma level with a large cerebellar hemorrhage and brain stem damage. This stereotactic evacuation of cerebellar hematoma using a plasminogen activator is effective for not only the removal of hematoma, but also for the treatment of secondary hydrocephalus following obstruction of the fourth ventricle by cerebellar hemorrhage.(ABSTRACT TRUNCATED AT 250 WORDS)
Yokote
H
H
Department of Neurological Surgery, Wakayama Medical College.
Komai
N
N
Nakai
E
E
Ueno
M
M
Hayashi
S
S
Terashita
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002526:Cerebellar Diseases / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D013238:Stereotaxic Techniques; D014057:Tomography, X-Ray Computed
D010960:Plasminogen Activators